Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer

Bibliography

• Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20(18 Suppl):1S-13S
   PubMed Web of Science ®Google Scholar
• Pfeiffer P, Clausen PP, Andersen K, Rose C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J cancer 1996;74(1):86-91
   PubMed Web of Science ®Google Scholar
• Rusch V, Klimstra D, Venkatraman E, Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumour progression. Clin Cancer Res 1997;3(4):515-22
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Bunn PA Jr, Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21(20):3798-807
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Caputo R, Bianco R, Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7(5):1459-65
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19(3):183-232
   PubMed Web of Science ®Google Scholar
• Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncology 2002;29(5 Suppl 14):38-44
   PubMed Web of Science ®Google Scholar
• Sartor CI. Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family. Semi Oncology 2000;27(6 Suppl 11):15-20, discussion 92-100
   PubMed Web of Science ®Google Scholar
• Volm M, Rittgen W, Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 1998;77(4):663-9
   PubMed Web of Science ®Google Scholar
• D'Amico TA, Massey M, Herndon JE II, A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999;117(4):736-43
   PubMed Web of Science ®Google Scholar
• Brabender J, Danenberg KD, Metzger R, Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001;7(7):1850-5
   PubMed Web of Science ®Google Scholar
• Selvaggi G, Novello S, Torri V, Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004;15(1):28-32
   PubMed Web of Science ®Google Scholar
• Meert AP, Martin B, Delmotte P, The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002;20(4):975-81
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358(11):1160-74
   PubMed Web of Science ®Google Scholar
• Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002;29(5 Suppl 14):3-9
   PubMed Web of Science ®Google Scholar
• Agelaki S, Georgoulias V. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. Expert Opin Emerg Drugs 2005;10(4):855-74
   PubMedGoogle Scholar
• Adjei AA. Novel combinations based on epidermal growth factor receptor inhibition. Clin Cancer Res 2006;12(14 Pt 2):4446s-4450s
   PubMed Web of Science ®Google Scholar
• Toker A, Yoeli-Lerner M. Akt signalling and cancer: surviving but not moving on. Cancer Res 2006;66(8):3963-6
   PubMed Web of Science ®Google Scholar
• Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 2006;6(3):231-41
   PubMed Web of Science ®Google Scholar
• Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumours: a new paradigm for cancer therapy. Cancer 2002;94(5):1593-611
   PubMed Web of Science ®Google Scholar
• Petit AM, Rak J, Hung MC, Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumour cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumours. Am J Pathol 1997;151(6):1523-30
   PubMed Web of Science ®Google Scholar
• Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 2000;10(7):505-10
   PubMed Web of Science ®Google Scholar
• Gibson S, Tu S, Oyer R, Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem 1999;274(25):17612-18
   PubMed Web of Science ®Google Scholar
• Kari C, Chan TO, Rocha de Quadros M, Rodeck U. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 2003;63(1):1-5
   PubMed Web of Science ®Google Scholar
• Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003;95(12):851-67
   PubMedGoogle Scholar
• Ciardiello F, De Vita F, Orditura M, Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. Expert Opin Emerg Drugs 2003;8(2):501-14
   PubMedGoogle Scholar
• Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24(17):2666-72
   PubMed Web of Science ®Google Scholar
• Oliveira S, van Bergen en Henegouwen PM, Storm G, Schiffelers RM. Molecular biology of epidermal growth factor receptor inhibition for cancer therapy. Expert Opin Biol Ther 2006;6(6):605-17
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-500
   PubMed Web of Science ®Google Scholar
• Guo M, Liu S, Lu F. Gefitinib-sensitizing mutations in esophageal carcinoma. N Engl J Med 2006;354(20):2193-4
   PubMed Web of Science ®Google Scholar
• Rosell R, Viteri S, Molina MA, Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Curr Opin Oncol 2009;22(2):112-20
   Web of Science ®Google Scholar
• Prigent SA, Nagane M, Lin H, Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 1996;271(41):25639-45
   PubMed Web of Science ®Google Scholar
• Lal A, Glazer CA, Martinson HM, Mutant epidermal growth factor receptor up-regulates molecular effectors of tumour invasion. Cancer Res 2002;62(12):3335-9
   PubMed Web of Science ®Google Scholar
• Sok JC, Coppelli FM, Thomas SM, Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12(17):5064-73
   PubMed Web of Science ®Google Scholar
• He Y, Zeng Q, Drenning SD, Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 1998;90(14):1080-7
   PubMed Web of Science ®Google Scholar
• Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 2003;4(7):397-406
   PubMed Web of Science ®Google Scholar
• Neninger E, Crombet T, Osorio M, Vaccination with EGF active immunotherapy improves survival in advanced non small cell lung cancer (NSCLC) patients: interim analysis of a randomized Phase II trial. ASCO Annual Meeting Part I of II. J Clin Oncol 2005;23(16S): abstract 7210
   Google Scholar
• Li S, Schmitz KR, Jeffrey PD, Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer cell 2005;7(4):301-11
   PubMed Web of Science ®Google Scholar
• Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994;269(44):27595-602
   PubMed Web of Science ®Google Scholar
• Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev 2006;6(9):714-27
   Google Scholar
• Kawaguchi Y, Kono K, Mimura K, Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007;120(4):781-7
   PubMed Web of Science ®Google Scholar
• Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007;298(1):70-82
   PubMed Web of Science ®Google Scholar
• Kurai J, Chikumi H, Hashimoto K, Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007;13(5):1552-61
   PubMed Web of Science ®Google Scholar
• Waksal HW. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 1999;18(4):427-36
   PubMed Web of Science ®Google Scholar
• Masui H, Moroyama T, Mendelsohn J. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res 1986;46(11):5592-8
   PubMed Web of Science ®Google Scholar
• Yang XD, Jia XC, Corvalan JR, Eradication of established tumours by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999;59(6):1236-43
   PubMed Web of Science ®Google Scholar
• Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993;53(19):4637-42
   PubMed Web of Science ®Google Scholar
• Milas L, Mason K, Hunter N, In vivo enhancement of tumour radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000;6(2):701-8
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Trigo J, Hitt R, Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25(16):2171-7
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-45
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Makhson A, Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27(5):663-71
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Maurel J, Fehrenbacher L, EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(14):2311-19
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17
   PubMed Web of Science ®Google Scholar
• Thienelt CD, Bunn PA Jr, Hanna N, Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005;23(34):8786-93
   PubMed Web of Science ®Google Scholar
• Robert F, Blumenschein G, Herbst RS, Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 2005;23(36):9089-96
   PubMed Web of Science ®Google Scholar
• Belani CP, Schreeder MT, Steis RG, Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage non small cell lung cancer: a multicenter phase 2 study. Cancer 2008;113(9):2512-17
   PubMed Web of Science ®Google Scholar
• Butts CA, Bodkin D, Middleman EL, Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007;25(36):5777-84
   PubMed Web of Science ®Google Scholar
• Rosell R, Robinet G, Szczesna A, Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008;19(2):362-9
   PubMed Web of Science ®Google Scholar
• Herbst RS, Chansky K, Kelly K, A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342. ASCO Annual Meeting. J Clin Oncol 2007;25(18S): abstract 7545
   Google Scholar
• Pirker R, Pereira JR, Szczesna A, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373(9674):1525-31
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26(21):3543-51
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27(8):1227-34
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Patel T, Dreisbach L, Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28(6):911-7
   PubMed Web of Science ®Google Scholar
• Pujol J, Lynch TJ, Rosell R, A meta-analysis of four randomized phase II/III trials adding cetuximab to platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC) [abstract O-9009]. Eur J Cancer 2009;7(2):508
   Google Scholar
• Hanna N, Lilenbaum R, Ansari R, Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006;24(33):5253-8
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18(10):2095-103
   PubMed Web of Science ®Google Scholar
• Kim ES, Mauer AM, William WN Jr, A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 2009;115(8):1713-22
   PubMed Web of Science ®Google Scholar
• Jalal S, Waterhouse D, Edelman MJ, Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group. J Thorac Oncol 2009;4(11):1420-4
   PubMed Web of Science ®Google Scholar
• Pfister DG, Su YB, Kraus DH, Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24(7):1072-8
   PubMed Web of Science ®Google Scholar
• Hughes S, Liong J, Miah A, A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study. J Thorac Oncol 2008;3(6):648-51
   PubMed Web of Science ®Google Scholar
• Blumenschein GR, Paulus R, Curran WJ, A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): a report of the 2 year and median survival (MS) for the RTOG 0324 trial. ASCO Annual Meeting. J Clin Oncol 2008;26: abstract 7516
   PubMedGoogle Scholar
• Govindan R, Bogart J, Wang X, Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. ASCO Annual Meeting. J Clin Oncol 2009;27(15S): abstract 7505
   PubMedGoogle Scholar
• Yang XD, Jia XC, Corvalan JR, Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001;38(1):17-23
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S, Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25(13):1658-64
   PubMed Web of Science ®Google Scholar
• Wirth LJ, Allen AM, Posner MR, Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol 2010;21(2):342-7
   PubMed Web of Science ®Google Scholar
• Socinski MA. Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. Clin Cancer Res 2007;13(15 Pt 2):s4597-601
   PubMed Web of Science ®Google Scholar
• Kim T. Technology evaluation: matuzumab, Merck KGaA. Curr Opin Mol Ther 2004;6(1):96-103
   PubMedGoogle Scholar
• Kollmannsberger C, Schittenhelm M, Honecker F, A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2006;17(6):1007-13
   PubMed Web of Science ®Google Scholar
• Boku N, Yamazaki K, Yamamoto N, Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumours in Japan. ASCO Annual Meeting. J Clin Oncol 2009;27: abstract e14574
   Web of Science ®Google Scholar
• Krishnamurthyreddy B, Vidyasagar MS, Koteshwar R. A phase IIb 4-arm open-label andomized study to assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. ASCO Annual Meeting. J Clin Oncol 2009;27(15S): abstract 6041
   Google Scholar
• Bebb DG, Brade AM, Smith C, Preliminary results of an escalating dose phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. ASCO Annual Meeting. J Clin Oncol 2008;26: abstract 3037
   Google Scholar
• Adams CW, Allison DE, Flagella K, Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006;55(6):717-27
   PubMed Web of Science ®Google Scholar
• Franklin MC, Carey KD, Vajdos FF, Insights into ErbB signalling from the structure of the ErbB2-pertuzumab complex. Cancer cell 2004;5(4):317-28
   PubMed Web of Science ®Google Scholar
• Herbst RS, Davies AM, Natale RB, Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res 2007;13(20):6175-81
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21(12):2237-46
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS, Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290(16):2149-58
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366(9496):1527-37
   PubMed Web of Science ®Google Scholar
• Fossella FV, DeVore R, Kerr RN, Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18(12):2354-62
   PubMed Web of Science ®Google Scholar
• Maruyama R, Nishiwaki Y, Tamura T, Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26(26):4244-52
   PubMed Web of Science ®Google Scholar
• Lee DH, Park K, Kim JH, Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010;16(4):1307-14
   PubMed Web of Science ®Google Scholar
• Cufer T, Vrdoljak E, Gaafar R, Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 2006;17(4):401-9
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372(9652):1809-18
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Douillard J-Y, Fukuoka M, Gefitinib versus Docetaxel in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC): meta-analysis from four randomized clinical trials. WCLC meeting, (A2,4), San Francisco; 2009
   Google Scholar
• Giaccone G, Herbst RS, Manegold C, Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1. J Clin Oncol 2004;22(5):777-84
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, Schiller JH, Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22(5):785-94
   PubMed Web of Science ®Google Scholar
• Crino L, Cappuzzo F, Zatloukal P, Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008;26(26):4253-60
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-57
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2009;11(2):121-8
   PubMed Web of Science ®Google Scholar
• Takeda K, Hida T, Sato T, Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 2010;28(5):753-60
   PubMed Web of Science ®Google Scholar
• Kelly K, Chansky K, Gaspar LE, Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26(15):2450-6
   PubMed Web of Science ®Google Scholar
• Inoue A, Saijo Y, Maemondo M, Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361(9352):137-9
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna A, Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25(12):1545-52
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R, TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23(25):5892-9
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L, SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. ASCO Annual Meeting. J Clin Oncol 2009;27(15S): abstract 8001
   Google Scholar
• Herbst RS, Sun Y, Korfee S, Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). ASCO Annual Meeting. J Clin Oncol 2009;27(18S): abstract CRA8003
   Google Scholar
• Natale RB, Thongprasert S, Greco FA, Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). ASCO Annual Meeting. J Clin Oncol 2009;27(15S): abstract 8009
   Google Scholar
• Wedge SR, Ogilvie DJ, Dukes M, ZD6474 inhibits vascular endothelial growth factor signalling, angiogenesis, and tumour growth following oral administration. Cancer Res 2002;62(16):4645-55
   PubMed Web of Science ®Google Scholar
• De Boer R, Arrieta O, Gottfried M, Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). ASCO Annual Meeting. J Clin Oncol 2009;27(15S): abstract 8010
   Google Scholar
• Li D, Ambrogio L, Shimamura T, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27(34):4702-11
   PubMed Web of Science ®Google Scholar
• De Greve JLP, Teugels E, De Mey J, Clinical activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2neu. WCLC meeting, (A6,7), San Francisco; 2009
   Google Scholar
• Stavridi F, Kristeleit R, Forster M, Activity of BIBW 2992, an oral irreversible EGFR/HER2 dual kinase inhibitor, in combination with weekly paclitaxel in non-small cell lung cancer. WCLC meeting, (PD3,1,5), San Francisco; 2009
   Google Scholar
• Yamamoto N, Tamura T, Takahashi T, Phase I open-label trial of continuous dose of BIBW 2992 in patients with advanced non-small cell lung cancer failing chemotherapy and/or erlotinib and/or gefitinib. WCLC meeting, (P1,264), San Francisco; 2009
   Google Scholar
• Yang C, Hirsh V, Cadranel J, Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX- Lung1): a preliminary report. ASCO Annual Meeting. J Clin Oncol 2009;27(15S): abstract 8062
   Google Scholar
• Shih J, Yang C, Su W, A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2). ASCO Annual Meeting. J Clin Oncol 2009;27(15S): abstract 8013
   PubMedGoogle Scholar
• Yang C-H, Shih J-Y, Su W-C, A novel irreversible EGFR/HER2 tyrosine kinase inhibitor, in chemonaive patients with adenocarcinoma of the lung and activating EGFR mutations. WCLC meeting, (A3,3 - BIBW 2992), San Francisco; 2009
   Google Scholar
• Gendreau SB, Ventura R, Keast P, Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res 2007;13(12):3713-23
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Kris MG, Miller VA, Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: results from Phase 2. ASCO Annual Meeting. J Clin Oncol 2008;26: abstract 8053
   PubMed Web of Science ®Google Scholar
• Miller VA, Wakelee HA, Lara PN, Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: preliminary results of a phase II trial. ASCO Annual Meeting. J Clin Oncol 2008;26: abstract 8028
   Web of Science ®Google Scholar
• Janne PA, Schellens JH, Engelman JA, Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC. ASCO Annual Meeting. J Clin Oncol 2008;26: abstract 8027
   Web of Science ®Google Scholar
• Janne PA, Reckamp K, Koczywas M, A Phase 2 Trial of PF-00299804 (PF299), an oral irreversible HER tyrosine kinase inhibitor (TKI), in patients (pts) with advanced NSCLC after failure of prior chemotherapy and erlotinib: preliminary efficacy and safety results. WCLC meeting, (A3,1), San Francisco; 2009
   Google Scholar
• Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007;5(3):203-20
   PubMed Web of Science ®Google Scholar
• Zhong H, Chiles K, Feldser D, Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumour angiogenesis and therapeutics. Cancer Res 2000;60(6):1541-5
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Bianco R, Damiano V, Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000;6(9):3739-47
   PubMed Web of Science ®Google Scholar
• Huang SM, Li J, Armstrong EA, Harari PM. Modulation of radiation response and tumour-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 2002;62(15):4300-6
   PubMed Web of Science ®Google Scholar
• Perrotte P, Matsumoto T, Inoue K, Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999;5(2):257-65
   PubMed Web of Science ®Google Scholar
• Groen HJ, Smit EF, Dingemans A. A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC). ASCO Annual Meeting. J of Clin Oncol 2007;25(18s): abstract 7625
   PubMedGoogle Scholar
• Fehrenbacher L, O'Neill V, Belani CP, A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. ASCO Annual Meeting. J Clin Oncol 2006;24(18s): abstract 7062
   Google Scholar
• Hainsworth J, Lin M, O' Connor P, Herbst R. A Phase III, multicenter, placebo- controlled, double-blind, randomized, clinical trial to evaluate the efficacy of bvacizumab (Avastin) in combination with erlotinib (Tarceva) compared with erlotinib alone for treatment of advanced non- small cell lung cancer (NSCLC) after failure of standard first line chemotherapy (BETA). IASLC meeting 11 – 13, Chicago; 2008
   Google Scholar
• Johnson B, Miller V, Amler L, Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advance. Eur J Cancer Suppl 2009;7(3):5
   Google Scholar
• Miller VA, O'Connor P, Soh C, A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). ASCO Annual Meeting. J Clin Oncol 2009;27:18s: abstract LBA8002
   Google Scholar
• Gandara D, Kim ES, Herbst RS, S0536: carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): a SWOG phase II study. ASCO Annual Meeting. J Clin Oncol 2009;27(15S): abstract 8015
   Google Scholar
• Herbst RS, Chansky K, Kelly K, A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342. J Clin Oncol 2007;25(18S):7545
   Google Scholar
• Tredaniel J, Descourt R, Moro-Sibilot D, Vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small cell lung cancer (NSCLC): a Phase I dose-escalation study. ASCO Annual Meeting. J Clin Oncol 2009;27(15S): abstract 8049
   Google Scholar
• Lind JS, Dingemans AC, Groen HJ, Smit EF. A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC). ASCO Annual Meeting. J Clin Oncol 2009;27(15S): abstract 8018
   Google Scholar
• Spigel DR, Greco AF. Burris HA III, Shipley DL, Friedman EK, Waterhouse DM, Whorf RC, Mitchell DR, Daniel DB, Zangmeister J, Sarnoff V, Hainsworth JD. A randomized double-blind placebo-controlled Phase II trial of sorafenib and erlotinib or erlotinib alone in peviously treated advanced non-small-cell lung cancer [abstract C1.5]. IASLC 13th World Conference on Lung Cancer, JTO 2009
   Google Scholar
• Miller VA, Kris MG, Shah N, Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22(6):1103-9
   PubMed Web of Science ®Google Scholar
• Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev 2006;6(10):803-12
   Google Scholar
• Wacker B, Nagrani T, Weinberg J, Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13(13):3913-21
   PubMed Web of Science ®Google Scholar
• Lenz HJ, Van Cutsem E, Khambata-Ford S, Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24(30):4914-21
   PubMed Web of Science ®Google Scholar
• Neal JW, Woytowitz D, Patel T, Skin rash as a surrogate marker of cetuximab efficacy in advanced NSCLC: a retrospective analysis of BMS099. WCLC meeting, (PD9,1,3), San Francisco; 2009
   Google Scholar
• West HL, Franklin WA, McCoy J, Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 2006;24(12):1807-13
   PubMed Web of Science ®Google Scholar
• Marchetti A, Martella C, Felicioni L, EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23(4):857-65
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L, SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 2009;27(15S): abstract 8001
   Google Scholar
• Soda M, Choi YL, Enomoto M, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561-6
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Mino-Kenudson M, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27(26):4247-53
   PubMed Web of Science ®Google Scholar
• Sobol RE, Astarita RW, Hofeditz C, Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst 1987;79(3):403-7
   PubMedGoogle Scholar
• Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumours. Semin oncol 2003;30(1 Suppl 1):3-11
   PubMed Web of Science ®Google Scholar
• Fontanini G, De Laurentiis M, Vignati S, Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998;4(1):241-9
   PubMed Web of Science ®Google Scholar
• Peled N, Yoshida K, Wynes WM, Hirsch FR. Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer. Ther Adv Med Oncol 2009;1(3):137-44
   PubMedGoogle Scholar
• Bailey LR, Janas M, Schmidt K, Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy. ASCO Annual Meeting. J Clin Oncol 2004;22(14S): abstract 7013
   Google Scholar
• Douillard JY, Shepherd FA, Hirsh V, Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28(5):744-52
   PubMed Web of Science ®Google Scholar
• Bailey L, Kris M, Wolf M, Tumour epidermal growth factor receptor (EGFR) expression levels does not predict for response in patients (pts) receiving gefitinib (“Iressa,”ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer (NSCLC): IDEAL 1 and 2. Proc AACR 2003;44:1362
   Google Scholar
• Fukuoka M, Wu Y, Thongprasert S, Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). ASCO Annual Meeting. J Clin Oncol 2009;27(15S): abstract 8006
   PubMedGoogle Scholar
• Hirsch FR, Varella-Garcia M, Bunn PA Jr, Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24(31):5034-42
   PubMed Web of Science ®Google Scholar
• Tsao MS, Sakurada A, Cutz JC, Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353(2):133-44
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Harbison C, Lowell L, K-ras mutation status, EGFR mutation status and increased EGFR gene copy number do not predict for cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small cell lung cancer. J Clin Oncol 2010;28:918-27
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Paz-Ares L, Pereira R, Molecular and clinical biomarkers of cetuximab efficacy: data from the phase III FLEX study in non–small-cell lung cancer [abstract B23]. J Thorac Oncol 2009;4(Suppl 1):S324
   Google Scholar
• Franklin WA, Gandara DR, Kim ES, SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC). ASCO Annual Meeting. J Clin Oncol 2009;27(15S): abstract 11076
   Google Scholar
• Zhu CQ, da Cunha Santos G, Ding K, Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26(26):4268-75
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Dziadziuszko R, Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res 2008;14(19):6317-23
   PubMed Web of Science ®Google Scholar
• Soulieres D, Ciuleanu TE, Stelmakh LV, Is there a relationship between increased EGFR gene copy number and the presence of activating EGFR mutations in advanced NSCLC? WCLC meeting, (A3,6), San Francisco; 2009
   Google Scholar
• Hirsch FR, Herbst RS, Olsen C, Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008;26(20):3351-7
   PubMed Web of Science ®Google Scholar
• Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25(5):587-95
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signalling pathway in lung cancers. Int J Cancer 2006;118(2):257-62
   PubMed Web of Science ®Google Scholar
• Bell DW, Lynch TJ, Haserlat SM, Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23(31):8081-92
   PubMed Web of Science ®Google Scholar
• Morita S, Okamoto I, Kobayashi K, Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2009;15(13):4493-8
   PubMed Web of Science ®Google Scholar
• Kalikaki A, Koutsopoulos A, Hatzidaki D, Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 2010;69(1):110-15
   Google Scholar
• Shepherd FA, Tsao MS. Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma. J Clin Oncol 2010;28(6):903-5
   PubMed Web of Science ®Google Scholar
• Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 2006;8(1):30-8
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23(11):2556-68
   PubMed Web of Science ®Google Scholar
• Massarelli E, Varella-Garcia M, Tang X, KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13(10):2890-6
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Garrett CR, Meropol NJ, Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25(22):3230-7
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O'Callaghan CJ, Karapetis CS, Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357(20):2040-8
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-65
   PubMed Web of Science ®Google Scholar
• Mack PC, Holland WS, Redman M, KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. ASCO Annual Meeting. J Clin Oncol 2009;27(15S): abstract 8022
   Google Scholar
• Linardou H, Dahabreh IJ, Kanaloupiti D, Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9(10):962-72
   PubMed Web of Science ®Google Scholar
• Hirsch F, Dziadziuszko R, Camidge D. Biomarker status correlates with clinical benefi t: Phase 2 study of single-agent erlotinib (E) or E intercalated with carboplatin and paclitaxel in an EGFR biomarker selected population. J Thorac Oncol 2008;3:S267
   Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352(8):786-92
   PubMed Web of Science ®Google Scholar
• Kuang Y, Rogers A, Yeap BY, Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009;15(8):2630-6
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2(3):e73
   PubMed Web of Science ®Google Scholar
• Maheswaran S, Sequist LV, Nagrath S, Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359(4):366-77
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalling. Science 2007;316(5827):1039-43
   PubMed Web of Science ®Google Scholar
• Guix M, Faber AC, Wang SE, Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008;118(7):2609-19
   PubMed Web of Science ®Google Scholar
• Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Ann Rev Med 2008;59:429-42
   PubMed Web of Science ®Google Scholar
• Kwak EL, Sordella R, Bell DW, Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005;102(21):7665-70
   PubMed Web of Science ®Google Scholar
• Rubin BP, Duensing A. Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumours. Lab Invest 2006;86(10):981-6
   PubMed Web of Science ®Google Scholar
• Camp ER, Summy J, Bauer TW, Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 2005;11(1):397-405
   PubMed Web of Science ®Google Scholar
• Jackman D, Pao W, Riely GJ, Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28(2):357-60
   PubMed Web of Science ®Google Scholar
• Riely GJ, Kris MG, Zhao B, Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007;13(17):5150-5
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Harbison CT, Hart LL, Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010;28(6):918-27
   PubMed Web of Science ®Google Scholar